{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:17:03Z","timestamp":1789503423708,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.vaccine.2016.01.062","type":"journal-article","created":{"date-parts":[[2016,2,6]],"date-time":"2016-02-06T04:03:18Z","timestamp":1454731398000},"page":"1412-1421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults"],"prefix":"10.1016","volume":"34","author":[{"given":"Alice","family":"Minhinnick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Satti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morven","family":"Wilkie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Stockdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zita-Rose Manjaly","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Lopez-Ramon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Poulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Vermaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Le Vert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Del Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergal","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.01.062_bib0115","series-title":"Global Tuberculosis Report 2014","author":"WHO","year":"2014"},{"issue":"9517","key":"10.1016\/j.vaccine.2016.01.062_bib0120","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","article-title":"Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness","volume":"367","author":"Trunz","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2016.01.062_bib0125","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/ije\/22.6.1154","article-title":"Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis","volume":"22","author":"Rodrigues","year":"1993","journal-title":"Int J Epidemiol"},{"issue":"8986","key":"10.1016\/j.vaccine.2016.01.062_bib0130","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","article-title":"Variation in protection by BCG: implications of and for heterologous immunity","volume":"346","author":"Fine","year":"1995","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2016.01.062_bib0135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1542\/peds.96.1.29","article-title":"The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature","volume":"96","author":"Colditz","year":"1995","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.vaccine.2016.01.062_bib0140","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1128\/IAI.01369-07","article-title":"The oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4bp domain protects mice against malaria","volume":"76","author":"Ogun","year":"2008","journal-title":"Infect Immun"},{"issue":"8","key":"10.1016\/j.vaccine.2016.01.062_bib0145","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1473-3099(06)70552-7","article-title":"Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design","volume":"6","author":"Ibanga","year":"2006","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2016.01.062_bib0150","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2016.01.062_bib0155","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1086\/590185","article-title":"Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa","volume":"198","author":"Hawkridge","year":"2008","journal-title":"J Infect Dis"},{"issue":"9871","key":"10.1016\/j.vaccine.2016.01.062_bib0160","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.062_bib0165","doi-asserted-by":"crossref","first-page":"e33555","DOI":"10.1371\/journal.pone.0033555","article-title":"Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates","volume":"7","author":"Spencer","year":"2012","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.vaccine.2016.01.062_bib0170","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.vaccine.2016.01.062_bib0175","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.vaccine.2012.12.042","article-title":"Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery","volume":"31","author":"Meyer","year":"2013","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2016.01.062_bib0180","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jim.2004.06.010","article-title":"Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies","volume":"291","author":"Hanekom","year":"2004","journal-title":"J Immunol Methods"},{"issue":"7","key":"10.1016\/j.vaccine.2016.01.062_bib0185","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.vaccine.2012.12.042","article-title":"Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery","volume":"31","author":"Meyer","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2016.01.062_bib0190","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/JVI.77.1.799-803.2003","article-title":"Overcoming immunity to a viral vaccine by DNA priming before vector boosting","volume":"77","author":"Yang","year":"2003","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2016.01.062_bib0195","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nm1592","article-title":"Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major","volume":"13","author":"Darrah","year":"2007","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2016.01.062_bib0200","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nri2274","article-title":"T-cell quality in memory and protection: implications for vaccine design","volume":"8","author":"Seder","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2016.01.062_bib0205","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.molimm.2009.11.005","article-title":"Humoral immunity in tuberculin skin test anergy and its role in high-risk persons exposed to active tuberculosis","volume":"47","author":"Encinales","year":"2010","journal-title":"Mol Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2016.01.062_bib0210","first-page":"542","article-title":"Role of complement activation and antibody in the interaction between Mycobacterium tuberculosis and human macrophages","volume":"50","author":"Manivannan","year":"2012","journal-title":"Indian J Exp Biol"},{"key":"10.1016\/j.vaccine.2016.01.062_bib0215","doi-asserted-by":"crossref","first-page":"351573","DOI":"10.1155\/2011\/351573","article-title":"Human T cell and antibody-mediated responses to the Mycobacterium tuberculosis recombinant 85A, 85B, and ESAT-6 antigens","volume":"2011","author":"Macedo","year":"2011","journal-title":"Clin Dev Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.062_bib0220","first-page":"449","article-title":"PPD-specific IgG1 antibody subclass upregulate tumour necrosis factor expression in PPD-stimulated monocytes: possible link with disease pathogenesis in tuberculosis","volume":"119","author":"Hussain","year":"2000","journal-title":"Clin Exp Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16001250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16001250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T14:20:28Z","timestamp":1654266028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16001250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0264410X16001250"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.01.062","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.01.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}